Atalaya Capital Management’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Atalaya Capital Management’s Portfolio PEARW Stock Details PEARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-8,333	Closed	-$8K	–	444
2021 Q3	$8K	Hold	8,333	–	–	﹤0.01%	326
2021 Q2	$12K	Hold	8,333	–	–	﹤0.01%	308
2021 Q1	$8K	Buy	+8,333	New	+$8.13K	﹤0.01%	251

Other funds holding PEARW

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Kingstown Capital Management New York $30.4M AUM 3.71% 1-Year Est. Return

Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

Atalaya Capital Management's PEARW Position: Q4 2021 in Review

Atalaya Capital Management sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q4 2021, closing a stake of 8,333 shares — an estimated $8K sold.

Atalaya Capital Management first reported a position in PEARW in Q1 2021 and held it in 3 quarters. The position peaked at $12K in Q2 2021. 44 funds tracked by Wall St. Rank hold PEARW as of Q4 2021.

Atalaya Capital Management reported no remaining Pear Therapeutics, Inc. Warrant position as of Q4 2021 after selling out during the quarter.
Atalaya Capital Management sold 8,333 Pear Therapeutics, Inc. Warrant shares in Q4 2021, an estimated $8K.
Atalaya Capital Management first reported a position in Pear Therapeutics, Inc. Warrant in Q1 2021 and held it in 3 quarters.
Atalaya Capital Management's Pear Therapeutics, Inc. Warrant position peaked at $12K in Q2 2021.
44 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q4 2021.

Based on Atalaya Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.